| Co-Investigator(Kenkyū-buntansha) |
間石 奈湖 北海道大学, 遺伝子病制御研究所, 助教 (00632423)
加賀 基知三 北海道大学, 大学病院, 講師 (80224335)
松居 喜郎 北海道大学, 大学病院, 教授 (90219379)
秋山 廣輔 北海道大学, 遺伝子病制御研究所, 客員研究員 (10609100)
|
|---|
| Budget Amount *help |
¥16,770,000 (Direct Cost: ¥12,900,000、Indirect Cost: ¥3,870,000)
Fiscal Year 2017: ¥4,030,000 (Direct Cost: ¥3,100,000、Indirect Cost: ¥930,000)
Fiscal Year 2016: ¥5,590,000 (Direct Cost: ¥4,300,000、Indirect Cost: ¥1,290,000)
Fiscal Year 2015: ¥7,150,000 (Direct Cost: ¥5,500,000、Indirect Cost: ¥1,650,000)
|
|---|
| Outline of Final Research Achievements |
Lung cancer patients showed higher serum Biglycan (BGN) than healthy control. In lung cancer patients, BGN level correlated with tumor size and invasiveness. Adenocarcinoma was associated with lower BGN than other lung cancers. In tumor tissue, BGN expression was observed in tumor endothelial cells. BGN expression in tissue correlated with serum BGN level. BGN expression in tumor tissue correlated with shorter overall survival.
Large number of mouse tumor and normal endothelial cells were used for tumor endothelial cell specific inhibitor screening. We could find several hit compounds.
We successfully induce SV40 and hTERT genes to human endothelial cells and grow them in long term.
|
